Company / Capital Expenditures
Aclaris Therapeutics, Inc. Capital Expenditures History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$111.0K
FY2025
5-year range
$111.0K / $1.3M
FY2021-FY2025
Trend
-91.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 9 years, ranging from $111,000 in FY2025 to $1M in FY2020.
Based on SEC 10-K filings.
$111,000 in FY2025 with a 5-year CAGR of -39.4%.
Declined from $308,000 to $111,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -43.2%
- 5-Year CAGR
- -39.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -39.4%, indicating a declining trend.
- In FY2025, capital expenditures decreased 91.5% year-over-year.
- Peak capital expenditures was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $111.0K | -91.5% |
| FY2024 | $1.3M | +325.0% |
| FY2023 | $308.0K | -49.1% |
| FY2022 | $605.0K | +96.4% |
| FY2021 | $308.0K | -77.3% |
| FY2020 | $1.4M | +9.8% |
| FY2019 | $1.2M | -8.9% |
| FY2018 | $1.4M | +167.5% |
| FY2017 | $507.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026